About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
T
Incorporating Novel Agents in 1L Therapy for Advanced cHL: PFS Data for Brentuximab Vedotin + AVD vs. ABVD, Efficacy Data for Nivo & Pembro Mono, and Nivo Combinations
By
Tatyana Feldman
2 Videos
130 views
May 3, 2021
0 Comments
Login to view comments.
Click here to Login
Featured Video
06:51
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…
Feat.
D. Tremblay
Featured Video
15:14
Icahn School of Medicine at Mount Sinai
Safety Profile of Ruxolitinib in Patients With MF
Feat.
D. Tremblay
Related Content
AUTOPLAY
ON
18:26
William Schaffner
Shingles (Herpes Zoster) Vaccination in Adults: What is the Importan…
21:05
Louisville Hematology Highlights
Why Are Our Hematopoietic Stem Cells in the Bone Marrow?
Feat.
R. Gale
11:12
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "SWOG S1826, a Randomized Study of Nivo-AV…
Feat.
A. Herrera
15:47
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "SWOG S1826 - Rationale, Results, and Clin…
Feat.
A. Evens
10:04
Stephen M. Ansell
NCCN Guidelines for the Treatment of cHL: A New Standard of Care
31:12
UChicago Medicine
Practice-Changing Abstracts in NHL and HL From ASH 2023
Feat.
S. Smith
08:59
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "SWOG S1826 Trial - Nivo-AVD vs. Bv-AVD in O…
Feat.
S. Rutherford
41:20
SOHO Highlights: State of the Art and Next Questions
SOHO Highlights - State of the Art & Next Questions: Hodgkin Lym…
Feat.
N. Bartlett
17:51
Penn Medicine Cellicon Valley '23: The Future of Cell and Gene Therapies
Chronic GVHD: A Case-Based Discussion
Feat.
L. Perry
15:18
UNC Lineberger Comprehensive Cancer Center
Hodgkin Lymphoma Management: Updates for 2023
Feat.
N. Grover
40:13
Fred Hutch 13th Annual Comprehensive Hematology & Oncology Review Course
Overview of Diagnosis and Treatment of Hodgkin's Lymphoma
Feat.
R. C. Lynch
21:26
Hackensack Meridian John Theurer Cancer Center
A+AVD in Frontline cHL: Barriers and Challenges
Feat.
T. Feldman
30:24
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Treatment of Older Patients With HL in the …
Feat.
A. Evens
42:09
University of Colorado Department of Medicine
Immunotherapy in Lymphomas: The Present and the Future
Feat.
M. Kamdar
28:57
Total Health
Highlights From Key Hematology Trials at ASCO® 2023
Feat.
J. Strauss
15:24
Total Health
2023 ASCO® Direct Philadelphia: Hodgkin Lymphoma Updates
Feat.
J. Svoboda
27:47
City of Hope
Chronic GVHD: Review Advances in Prevention, Novel Endpoints, and Ta…
Feat.
I. Amanam
23:24
SOHO Brazil 2023
2023 SOHO® Brazil: "How I Sequence New Agents in First and Seco…
Feat.
A. Moskowitz
08:02
ASH 2022 Conference Coverage
ASH 2022 Results From Phase III BMT CTN 1703: Post-Transplant Cyclop…
Feat.
S. Holtan
10:21
SOHO 2023 Eleventh Annual Meeting
SOHO 2023 Next Questions: HL
Feat.
A. Herrera
